Skip to main content
Top
Published in: Journal of Diabetes & Metabolic Disorders 1/2017

Open Access 01-12-2017 | Research article

Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach

Authors: Shivani Srivastava, Priya Shree, Yamini Bhusan Tripathi

Published in: Journal of Diabetes & Metabolic Disorders | Issue 1/2017

Login to get access

Abstract

Background

We had earlier reported that the extract of Pueraria tuberosa significantly inhibits DPP-IV enzyme, resulting in glucose tolerance response in rats. In this study, we have explored the active phytochemicals responsible for this potential. The results have been validated in both fasting and postprandial states in the plasma of normal rats and also in fasting blood and intestinal homogenates of diabetic models.

Methods

Pueraria tuberosa water extract (PTWE) was administered to normal Charles Foster rats for 35 days and to diabetic model (65 mg/kg bw) for 10 days. After treatments, oral glucose tolerance test (OGTT) and insulin was done for 90 min, and the changes in the levels of GLP-1, GIP, and DPP-IV activities were monitored in fasting and postprandial states. In the case of the diabetic model, DPP-IV activity was measured in intestinal homogenate and basal insulin in plasma. The components of PTWE were analyzed via HPLC-MS based on their chemical formula, molecular mass, and retention time. Using the molecular docking study, we have selected the top five components having strong binding energy with DPP-IV.

Results

The increase in secretion of GLP-1 and GIP was significantly higher in the postprandial state when compared to fasting condition. GLP-1 plasma concentration increased by 5.8 and 2.9 folds and GIP increased by 8.7 and 2.4 folds in PTWE and control rats, respectively. In contrast, the postprandial decrease in DPP-IV specific activities was recorded at 2.3 and 1.4 folds. The response in OGTT and insulin was also consistent with these changes. In comparison to diabetic controls, PTWE-administered rats showed decreased DPP-IV activity in the intestine, leading to enhanced basal insulin concentration. Through molecular docking, we found Puerarone and Robinin to be the most potential phytochemicals of PTWE for DPP-IV inhibition. Binding energy (kcal/mol) and dissociation constant (pM) of Robinin with DPP-IV protein were found to be 7.543 and 2,957,383.75, respectively. For Puerarone, it was 7.376 and 3,920,309, respectively.

Conclusions

Thus, this study provides the novel active components that contribute to the DPP-IV inhibitory property of PTWE.
Literature
1.
go back to reference Craddy P, Palin H-J, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014;5:1–41.CrossRefPubMedPubMedCentral Craddy P, Palin H-J, Johnson KI. Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison. Diabetes Ther. 2014;5:1–41.CrossRefPubMedPubMedCentral
2.
go back to reference Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J. Endocrinol Metab. 2016;20:254–67. Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J. Endocrinol Metab. 2016;20:254–67.
3.
go back to reference Baggio LL, Drucker DJ, Andryuk PJ, Lu K, Stein P, Khatami H, et al. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.CrossRefPubMed Baggio LL, Drucker DJ, Andryuk PJ, Lu K, Stein P, Khatami H, et al. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132:2131–57.CrossRefPubMed
4.
go back to reference Semaan D. In vitro anti-diabetic and anti-obesity activities of compounds from the Cuban medicinal plant, Allophylus cominia (L.) Sw. University of Strathclyde; 2014. Semaan D. In vitro anti-diabetic and anti-obesity activities of compounds from the Cuban medicinal plant, Allophylus cominia (L.) Sw. University of Strathclyde; 2014.
5.
go back to reference Chakrabarti R, Bhavtaran S, Narendra P, Varghese N, Vanchhawng L. Sham Shihabudeen MH, et al. Dipeptidyl Peptidase-IV Inhibitory Activity of Berberis aristata. 2011;4:158–63. Chakrabarti R, Bhavtaran S, Narendra P, Varghese N, Vanchhawng L. Sham Shihabudeen MH, et al. Dipeptidyl Peptidase-IV Inhibitory Activity of Berberis aristata. 2011;4:158–63.
6.
go back to reference Yogisha S, Raveesha KA. Dipeptidyl Peptidase IV Inhibitory activity of Mangifera Indica. J Nat Prod. 2010;3:76–9. Yogisha S, Raveesha KA. Dipeptidyl Peptidase IV Inhibitory activity of Mangifera Indica. J Nat Prod. 2010;3:76–9.
7.
go back to reference Bower AM, Real Hernandez LM, Berhow MA, de Mejia EG. Bioactive compounds from culinary herbs inhibit a molecular target for type 2 diabetes management, dipeptidyl peptidase IV. J Agric Food Chem. 2014;62:6147–58.CrossRefPubMed Bower AM, Real Hernandez LM, Berhow MA, de Mejia EG. Bioactive compounds from culinary herbs inhibit a molecular target for type 2 diabetes management, dipeptidyl peptidase IV. J Agric Food Chem. 2014;62:6147–58.CrossRefPubMed
8.
go back to reference Fan J, Johnson MH, Lila MA, Yousef G, de Mejia EG. Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: implications in diabetes management. Evid Based Complement Alternat Med. 2013;2013:479–505. Fan J, Johnson MH, Lila MA, Yousef G, de Mejia EG. Berry and citrus phenolic compounds inhibit dipeptidyl peptidase IV: implications in diabetes management. Evid Based Complement Alternat Med. 2013;2013:479–505.
9.
go back to reference Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem. 2009;24:1061–6.CrossRefPubMed Al-masri IM, Mohammad MK, Tahaa MO. Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine. J Enzyme Inhib Med Chem. 2009;24:1061–6.CrossRefPubMed
10.
11.
go back to reference Yousefi E, Zareiy S, Zavoshy R, Noroozi M, Jahanihashemi H, Ardalani H. Fenugreek: A therapeutic complement for patients with borderline hyperlipidemia: A randomised, double-blind, placebo-controlled, clinical trial. Adv Integr Med. 2017;4:31–5. Yousefi E, Zareiy S, Zavoshy R, Noroozi M, Jahanihashemi H, Ardalani H. Fenugreek: A therapeutic complement for patients with borderline hyperlipidemia: A randomised, double-blind, placebo-controlled, clinical trial. Adv Integr Med. 2017;4:31–5.
12.
go back to reference Ardalani H, Moghadam MH, Rahimi R, Soltani J, Mozayanimonfared A, Moradi M, et al. Sumac as a novel adjunctive treatment in hypertension: a randomized, double-blind, placebo-controlled clinical trial. RSC Adv. 2016;6:11507–12.CrossRef Ardalani H, Moghadam MH, Rahimi R, Soltani J, Mozayanimonfared A, Moradi M, et al. Sumac as a novel adjunctive treatment in hypertension: a randomized, double-blind, placebo-controlled clinical trial. RSC Adv. 2016;6:11507–12.CrossRef
13.
go back to reference Jandaghi P, Noroozi M, Ardalani H, Alipour M. Lemon balm: A promising herbal therapy for patients with borderline hyperlipidemia—A randomized double-blind placebo-controlled clinical trial. Complement Ther Med. 2016;26:136–40. Jandaghi P, Noroozi M, Ardalani H, Alipour M. Lemon balm: A promising herbal therapy for patients with borderline hyperlipidemia—A randomized double-blind placebo-controlled clinical trial. Complement Ther Med. 2016;26:136–40.
14.
go back to reference Hypoglycemic effects of Berberis aristata and Tamarindus indica extracts in vitro. Bull. Fac. Pharmacy, Cairo Univ. 2017;55:91–4. Hypoglycemic effects of Berberis aristata and Tamarindus indica extracts in vitro. Bull. Fac. Pharmacy, Cairo Univ. 2017;55:91–4.
15.
go back to reference Srivastava S, Koley TK, Singh SK, Tripathi YB. The tuber extract of pueraria tuberosa linn.competitively inhibits dpp-iv activity in normoglycemic rats. Int. J Pharm Pharm Sci. 2015;7:7–11. Srivastava S, Koley TK, Singh SK, Tripathi YB. The tuber extract of pueraria tuberosa linn.competitively inhibits dpp-iv activity in normoglycemic rats. Int. J Pharm Pharm Sci. 2015;7:7–11.
16.
go back to reference Tripathi AK, Kohli S. Anti-diabetic activity and phytochemical screening of crude extracts of PuerariaTuberosa DC. (FABACEAE) grown in India on STZ -induced diabetic rats. Asian J. Med. Pharm Res. 2013;3:66–73. Tripathi AK, Kohli S. Anti-diabetic activity and phytochemical screening of crude extracts of PuerariaTuberosa DC. (FABACEAE) grown in India on STZ -induced diabetic rats. Asian J. Med. Pharm Res. 2013;3:66–73.
17.
go back to reference Tripathi YB, Shukla R, Pandey N, Pandey V, Kumar M. An extract of Pueraria tuberosa tubers attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in the kidney of diabetic rats. J Diabetes. 2017;9:123–32.CrossRefPubMed Tripathi YB, Shukla R, Pandey N, Pandey V, Kumar M. An extract of Pueraria tuberosa tubers attenuates diabetic nephropathy by upregulating matrix metalloproteinase-9 expression in the kidney of diabetic rats. J Diabetes. 2017;9:123–32.CrossRefPubMed
18.
go back to reference Yadav D, Kumar M, Tripathi YB. Methanolic extract of tubers of Pueraria Tuberosa Linn. Ameliorates glycerol induced acute kidney injury in rats. J Chem Pharm Res. 2016;8:133–9. Yadav D, Kumar M, Tripathi YB. Methanolic extract of tubers of Pueraria Tuberosa Linn. Ameliorates glycerol induced acute kidney injury in rats. J Chem Pharm Res. 2016;8:133–9.
19.
go back to reference Tripathi Y, Pandey N, Yadav D, Pandey V. Anti-inflammatory effect of Pueraria tuberosa extracts through improvement in activity of red blood cell anti-oxidant enzymes. AYU (An Int. Q. J. Res. Ayurveda). 2013;34:297.CrossRef Tripathi Y, Pandey N, Yadav D, Pandey V. Anti-inflammatory effect of Pueraria tuberosa extracts through improvement in activity of red blood cell anti-oxidant enzymes. AYU (An Int. Q. J. Res. Ayurveda). 2013;34:297.CrossRef
20.
go back to reference She S, Liu W, Li T, Hong Y, Haneda M, Fitzl G, et al. Effects of puerarin in STZ-induced diabetic rats by oxidative stress and the TGF-β1/Smad2 pathway. Food Funct. 2014 May;5(5):944–50.CrossRefPubMed She S, Liu W, Li T, Hong Y, Haneda M, Fitzl G, et al. Effects of puerarin in STZ-induced diabetic rats by oxidative stress and the TGF-β1/Smad2 pathway. Food Funct. 2014 May;5(5):944–50.CrossRefPubMed
21.
go back to reference Fu-Liang X, Xiao-Hui S, Lu G, Xiang-Liang Y, Hui-Bi X. Puerarin protects rat pancreatic islets from damage by hydrogen peroxide. Eur J Pharmacol. 2006;529:1–7.CrossRef Fu-Liang X, Xiao-Hui S, Lu G, Xiang-Liang Y, Hui-Bi X. Puerarin protects rat pancreatic islets from damage by hydrogen peroxide. Eur J Pharmacol. 2006;529:1–7.CrossRef
22.
go back to reference Li Z, Shangguan Z, Liu Y, Wang J, Li X, Yang S, et al. Puerarin protects pancreatic β-cell survival via PI3K/Akt signaling pathway. J Mol Endocrinol BioScientifica. 2014;53:71–9.CrossRef Li Z, Shangguan Z, Liu Y, Wang J, Li X, Yang S, et al. Puerarin protects pancreatic β-cell survival via PI3K/Akt signaling pathway. J Mol Endocrinol BioScientifica. 2014;53:71–9.CrossRef
23.
go back to reference Yang L, Yao D, Yang H, Wei Y, Peng Y, Ding Y, et al. Puerarin protects pancreatic β-cells in obese diabetic mice via activation of GLP-1R signaling. Mol Endocrinol. 2016;30:361–71.CrossRefPubMedPubMedCentral Yang L, Yao D, Yang H, Wei Y, Peng Y, Ding Y, et al. Puerarin protects pancreatic β-cells in obese diabetic mice via activation of GLP-1R signaling. Mol Endocrinol. 2016;30:361–71.CrossRefPubMedPubMedCentral
24.
go back to reference Arora N, Singh VK, Shah K, Pandey-Rai S. Qualitative and quantitative analysis of 3D predicted arachidonate 15-lipoxygenase-B (15-LOX-2) from Homo Sapiens. Bioinformation. 2012;8:555–61.CrossRefPubMedPubMedCentral Arora N, Singh VK, Shah K, Pandey-Rai S. Qualitative and quantitative analysis of 3D predicted arachidonate 15-lipoxygenase-B (15-LOX-2) from Homo Sapiens. Bioinformation. 2012;8:555–61.CrossRefPubMedPubMedCentral
25.
go back to reference Huang B. MetaPocket: a meta approach to improve protein ligand binding site prediction. Omi. A J. Integr Biol. 2009;13:325–30. Huang B. MetaPocket: a meta approach to improve protein ligand binding site prediction. Omi. A J. Integr Biol. 2009;13:325–30.
27.
go back to reference Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur. J. Endocrinol. 2006;155:485–93.CrossRefPubMed Ryskjaer J, Deacon CF, Carr RD, Krarup T, Madsbad S, Holst J, et al. Plasma dipeptidyl peptidase-IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake. Eur. J. Endocrinol. 2006;155:485–93.CrossRefPubMed
28.
go back to reference Venkatesham A, Srinivas M, Krishna DR, Narayana P. Differential expression of dipeptidyl peptidase-IV (DPP-IV) in Indian type-2 diabetic population. J Assoc Physicians India. 2009;57:627–30.PubMed Venkatesham A, Srinivas M, Krishna DR, Narayana P. Differential expression of dipeptidyl peptidase-IV (DPP-IV) in Indian type-2 diabetic population. J Assoc Physicians India. 2009;57:627–30.PubMed
29.
go back to reference Allenki V, Devarakonda RK, Anreddy RNR, Pantam N, Yellu NR. Fasting and post prandial monitoring of dipeptidyl peptidase-iv (Dpp-iv) – a biomarker to assess incretin response in Type-2 diabetes. Stamford. J Pharm Sci. 2010;2:81–5. Allenki V, Devarakonda RK, Anreddy RNR, Pantam N, Yellu NR. Fasting and post prandial monitoring of dipeptidyl peptidase-iv (Dpp-iv) – a biomarker to assess incretin response in Type-2 diabetes. Stamford. J Pharm Sci. 2010;2:81–5.
30.
go back to reference Altenhofen D, da Luz G, Frederico MJS, Venzke D, Brich M, Vigil S, et al. Bis-Pyrano Prenyl Isoflavone improves glucose homeostasis by inhibiting dipeptidyl Peptidase-4 in hyperglycemic rats. J Cell Biochem. 2017;118:92–103.CrossRefPubMed Altenhofen D, da Luz G, Frederico MJS, Venzke D, Brich M, Vigil S, et al. Bis-Pyrano Prenyl Isoflavone improves glucose homeostasis by inhibiting dipeptidyl Peptidase-4 in hyperglycemic rats. J Cell Biochem. 2017;118:92–103.CrossRefPubMed
31.
go back to reference Wootten D, Simms J, Koole C, Woodman OL, Summers RJ, Christopoulos A, et al. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J Pharmacol Exp Ther. 2011;336:540–50.CrossRefPubMed Wootten D, Simms J, Koole C, Woodman OL, Summers RJ, Christopoulos A, et al. Modulation of the glucagon-like peptide-1 receptor signaling by naturally occurring and synthetic flavonoids. J Pharmacol Exp Ther. 2011;336:540–50.CrossRefPubMed
32.
go back to reference Asthana S, Agarwal T, Singothu S, Samal A, Banerjee I, Pal K, et al. Molecular docking and interactions of Pueraria Tuberosa with vascular endothelial growth factor receptors. Indian. J Pharm Sci. 2015;77:439–45. Asthana S, Agarwal T, Singothu S, Samal A, Banerjee I, Pal K, et al. Molecular docking and interactions of Pueraria Tuberosa with vascular endothelial growth factor receptors. Indian. J Pharm Sci. 2015;77:439–45.
33.
go back to reference Shukla R, Pandey N, Banerjee S, Tripathi YB. Effect of extract of Pueraria Tuberosa on expression of hypoxia inducible factor-1α and vascular endothelial growth factor in kidney of diabetic rats. Biomed Pharmacother. 2017;93:276–85.CrossRefPubMed Shukla R, Pandey N, Banerjee S, Tripathi YB. Effect of extract of Pueraria Tuberosa on expression of hypoxia inducible factor-1α and vascular endothelial growth factor in kidney of diabetic rats. Biomed Pharmacother. 2017;93:276–85.CrossRefPubMed
34.
go back to reference Samikannu B, Chen C, Lingwal N, Padmasekar M, Engel FB, Linn T. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway. PLoS One. 2013;8:e82639.CrossRefPubMedPubMedCentral Samikannu B, Chen C, Lingwal N, Padmasekar M, Engel FB, Linn T. Dipeptidyl peptidase IV inhibition activates CREB and improves islet vascularization through VEGF-A/VEGFR-2 signaling pathway. PLoS One. 2013;8:e82639.CrossRefPubMedPubMedCentral
35.
go back to reference Bokkenheuser VD, Shackleton CH, Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem J. 1987 Dec 15;248(3):953–6.CrossRefPubMedPubMedCentral Bokkenheuser VD, Shackleton CH, Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem J. 1987 Dec 15;248(3):953–6.CrossRefPubMedPubMedCentral
36.
go back to reference Morikawa T, Ninomiya K, Akaki J, Kakihara N, Kuramoto H, Matsumoto Y, et al. Dipeptidyl peptidase-IV inhibitory activity of dimeric dihydrochalcone glycosides from flowers of Helichrysum Arenarium. J Nat Med. 2015;69:494–506.CrossRefPubMedPubMedCentral Morikawa T, Ninomiya K, Akaki J, Kakihara N, Kuramoto H, Matsumoto Y, et al. Dipeptidyl peptidase-IV inhibitory activity of dimeric dihydrochalcone glycosides from flowers of Helichrysum Arenarium. J Nat Med. 2015;69:494–506.CrossRefPubMedPubMedCentral
37.
go back to reference Pathak R, Bridgeman MB. Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the Management of Diabetes. P T MediMedia. 2010;35:509–13. Pathak R, Bridgeman MB. Dipeptidyl Peptidase-4 (DPP-4) inhibitors in the Management of Diabetes. P T MediMedia. 2010;35:509–13.
Metadata
Title
Active phytochemicals of Pueraria tuberosa for DPP-IV inhibition: in silico and experimental approach
Authors
Shivani Srivastava
Priya Shree
Yamini Bhusan Tripathi
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Journal of Diabetes & Metabolic Disorders / Issue 1/2017
Electronic ISSN: 2251-6581
DOI
https://doi.org/10.1186/s40200-017-0328-0

Other articles of this Issue 1/2017

Journal of Diabetes & Metabolic Disorders 1/2017 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.